Evidence map›Paper›PMID 29176662›Full record

ArticleBlood cancer journal2017

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.

Maxim Norkin, Lakshmikanth Katragadda, Fei Zou, Sican Xiong, Myron Chang, Yunfeng Dai, Jack W Hsu, Jan S Moreb, Helen Leather, Hemant S Murthy and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maxim NorkinDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. norkinm@ufl.edu.
Lakshmikanth KatragaddaDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Fei ZouDepartment of Biostatistics, College of Medicine, University of Florida, Gainesville, FL, USA.
Sican XiongDepartment of Biostatistics, College of Medicine, University of Florida, Gainesville, FL, USA.
Myron ChangDepartment of Biostatistics, College of Medicine, University of Florida, Gainesville, FL, USA.
Yunfeng DaiDepartment of Biostatistics, College of Medicine, University of Florida, Gainesville, FL, USA.
Jack W HsuDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Jan S MorebDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Helen LeatherDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Hemant S MurthyDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Nosha FarhadfarDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Ying LiDepartment of Pathology, College of Medicine, University of Florida, Gainesville, FL, USA.
Robert HromasDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-1916-6276
Randy A BrownDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Christopher R CogleDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
John R WingardDivision of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsed acute myeloid leukemia (AML) is a significant challenge after allogeneic hematopoietic cell transplant (HCT). Multiparameter flow cytometry (MFC), conventional cytogenetics (CG), and fluorescence in situ hybridization (FISH) are routinely performed on bone marrow specimens prior to HCT to assess disease status. We questioned the extent by which pre-HCT evidence of minimal residual disease (MRD) detected by these standard assays, corresponded with post-HCT relapse. We conducted a single center, retrospective study of 166 AML patients who underwent HCT. Thirty-eight of one hundred sixty-six (23%) patients in complete remission (CR) or CR with incomplete count recovery (CRi) had MRD detectable by MFC, CG, or FISH. MRD was more frequently seen in patients with poor risk karyotype at diagnosis (P = 0.011). MRD-negative patients (MRD

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedCytogenetic AnalysisDisease-Free SurvivalFemaleFlow CytometryGraft vs Host DiseaseHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosis

Identifiers

PMID29176662
PMCPMC5802525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.